VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. ( NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH Foundation’s annual Familial Hypercholesterolemia (FH) Awareness Day.
Interim Chief Executive Officer Jeff Hackman said, "We share The FH Foundation’s mission of increasing awareness of FH, including homozygous FH (HoFH), a very serious and often undiagnosed disease. Education and awareness help to support early diagnosis and intervention. These are critical steps towards making an impact for people living with the disease.”
FH is a genetic condition that impacts the body’s ability to remove cholesterol that the body naturally produces. As a result, blood cholesterol levels are significantly elevated. There are two forms of the disease: heterozygous FH (HeFH), in which the genetic defect causing the impairment is inherited from one parent; and HoFH, in which the genetic defect is inherited from both parents. HoFH is the most severe form of the disorder.
Established in 2012, FH Awareness Day is a campaign initiated by the FH Foundation to raise awareness of FH in the general public. This annual event is held during National Cholesterol Education Month. As part of the event this year, the FH Foundation is highlighting FH Can’t Wait, a national public awareness and advocacy campaign which aims to ensure that anyone with a family history of early cardiac events and high cholesterol are screened for FH.
To learn more about familial hypercholesterolemia, visit www.thefhfoundation.org.
About Novelion Therapeutics
Novelion Therapeutics is a global biopharmaceutical company dedicated to developing and commercializing therapies that deliver new standards of care for people living with rare and underserved metabolic diseases. Our goal is to develop and bring to market transformational therapies that have the potential to significantly change the treatment paradigm for patients affected by a variety of rare and metabolic diseases, including diseases associated with low leptin, such as low-leptin associated obesity. With a global footprint and an established commercial portfolio, including MYALEPT® (metreleptin) and JUXTAPID® (lomitapide), our business is supported by differentiated treatments that treat severe and rare diseases.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
[email protected]
